Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Kaleido Biosciences, Inc. (KLDO)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
4 days ago | Zacks Investment Research
4 days ago | GlobeNewsWire
5 days ago | GlobeNewsWire
5 days ago | GlobeNewsWire
a week ago | GlobeNewsWire
2 weeks ago | Zacks Investment Research
2 months ago | GlobeNewsWire
3 months ago | GlobeNewsWire
3 months ago | GlobeNewsWire
4 months ago | GlobeNewsWire
About:
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.